

COVID-19 Impact on Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C7A7A44100ACEN.html>

Date: August 2020

Pages: 132

Price: US\$ 3,900.00 (Single User License)

ID: C7A7A44100ACEN

Abstracts

This report focuses on the global Primary Sclerosing Cholangitis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Sclerosing Cholangitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. The key players covered in this study

Allergan

Glenmark

Impax Laboratories

Mylan

Teva Pharmaceuticals

Dr. Falk Pharma

Daewoong Pharmaceutical

Epic Pharma

Mitsubishi Tanabe Pharma

Lannett

Bruschettini

Shanghai Pharma

Grindeks

Acorda Therapeutics

Gilead Sciences

Intercept Pharmaceuticals

Shire Plc

NGM Biopharmaceuticals

Conatus Pharmaceuticals

Durect Corporation

Sirnaomics

Shenzhen HighTide Biopharmaceuticals

Market segment by Type, the product can be split into

Liver Transplantation Operation

UDCA Drugs

PSC Drugs

Market segment by Application, split into

Hospital

Clinics

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Primary Sclerosing Cholangitis Treatment status, future forecast, growth opportunity, key market and key players.

To present the Primary Sclerosing Cholangitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Primary Sclerosing Cholangitis Treatment are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue

1.4 Market Analysis by Type

1.4.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Liver Transplantation Operation

1.4.3 UDCA Drugs

1.4.4 PSC Drugs

1.5 Market by Application

1.5.1 Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2020 VS 2026

1.5.2 Hospital

1.5.3 Clinics

1.5.4 Other

1.6 Coronavirus Disease 2019 (Covid-19): Primary Sclerosing Cholangitis Treatment Industry Impact

1.6.1 How the Covid-19 is Affecting the Primary Sclerosing Cholangitis Treatment Industry

1.6.1.1 Primary Sclerosing Cholangitis Treatment Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Primary Sclerosing Cholangitis Treatment Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Primary Sclerosing Cholangitis Treatment Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Primary Sclerosing Cholangitis Treatment Market Perspective (2015-2026)

COVID-19 Impact on Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2020-2026

2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Regions

2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Share by Regions (2015-2020)

2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Primary Sclerosing Cholangitis Treatment Market Growth Strategy

2.3.6 Primary Interviews with Key Primary Sclerosing Cholangitis Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Market Size

3.1.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue (2015-2020)

3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2015-2020)

3.1.3 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio

3.2.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2019

3.3 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served

3.4 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service

3.5 Date of Enter into Primary Sclerosing Cholangitis Treatment Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2015-2020)

4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2021-2026)

5 PRIMARY SCLEROSING CHOLANGITIS TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)

6.2 Primary Sclerosing Cholangitis Treatment Key Players in North America (2019-2020)

6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)

6.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)

7.2 Primary Sclerosing Cholangitis Treatment Key Players in Europe (2019-2020)

7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)

7.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)

8.2 Primary Sclerosing Cholangitis Treatment Key Players in China (2019-2020)

8.3 China Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)

8.4 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

9 JAPAN

- 9.1 Japan Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
- 9.2 Primary Sclerosing Cholangitis Treatment Key Players in Japan (2019-2020)
- 9.3 Japan Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
- 9.4 Japan Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
- 10.2 Primary Sclerosing Cholangitis Treatment Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
- 10.4 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
- 11.2 Primary Sclerosing Cholangitis Treatment Key Players in India (2019-2020)
- 11.3 India Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
- 11.4 India Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
- 12.2 Primary Sclerosing Cholangitis Treatment Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
- 12.4 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

- 13.1 Allergan
 - 13.1.1 Allergan Company Details

- 13.1.2 Allergan Business Overview and Its Total Revenue
- 13.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
- 13.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020))
- 13.1.5 Allergan Recent Development
- 13.2 Glenmark
 - 13.2.1 Glenmark Company Details
 - 13.2.2 Glenmark Business Overview and Its Total Revenue
 - 13.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
 - 13.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.2.5 Glenmark Recent Development
- 13.3 Impax Laboratories
 - 13.3.1 Impax Laboratories Company Details
 - 13.3.2 Impax Laboratories Business Overview and Its Total Revenue
 - 13.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
 - 13.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.3.5 Impax Laboratories Recent Development
- 13.4 Mylan
 - 13.4.1 Mylan Company Details
 - 13.4.2 Mylan Business Overview and Its Total Revenue
 - 13.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
 - 13.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.4.5 Mylan Recent Development
- 13.5 Teva Pharmaceuticals
 - 13.5.1 Teva Pharmaceuticals Company Details
 - 13.5.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
 - 13.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
 - 13.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.5.5 Teva Pharmaceuticals Recent Development
- 13.6 Dr. Falk Pharma
 - 13.6.1 Dr. Falk Pharma Company Details
 - 13.6.2 Dr. Falk Pharma Business Overview and Its Total Revenue
 - 13.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
 - 13.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

- 13.6.5 Dr. Falk Pharma Recent Development
- 13.7 Daewoong Pharmaceutical
 - 13.7.1 Daewoong Pharmaceutical Company Details
 - 13.7.2 Daewoong Pharmaceutical Business Overview and Its Total Revenue
 - 13.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
 - 13.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.7.5 Daewoong Pharmaceutical Recent Development
- 13.8 Epic Pharma
 - 13.8.1 Epic Pharma Company Details
 - 13.8.2 Epic Pharma Business Overview and Its Total Revenue
 - 13.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
 - 13.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.8.5 Epic Pharma Recent Development
- 13.9 Mitsubishi Tanabe Pharma
 - 13.9.1 Mitsubishi Tanabe Pharma Company Details
 - 13.9.2 Mitsubishi Tanabe Pharma Business Overview and Its Total Revenue
 - 13.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
 - 13.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.9.5 Mitsubishi Tanabe Pharma Recent Development
- 13.10 Lannett
 - 13.10.1 Lannett Company Details
 - 13.10.2 Lannett Business Overview and Its Total Revenue
 - 13.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
 - 13.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 13.10.5 Lannett Recent Development
- 13.11 Bruschettini
 - 10.11.1 Bruschettini Company Details
 - 10.11.2 Bruschettini Business Overview and Its Total Revenue
 - 10.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
 - 10.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 10.11.5 Bruschettini Recent Development
- 13.12 Shanghai Pharma

- 10.12.1 Shanghai Pharma Company Details
- 10.12.2 Shanghai Pharma Business Overview and Its Total Revenue
- 10.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
- 10.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
- 10.12.5 Shanghai Pharma Recent Development
- 13.13 Grindeks
 - 10.13.1 Grindeks Company Details
 - 10.13.2 Grindeks Business Overview and Its Total Revenue
 - 10.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
 - 10.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 10.13.5 Grindeks Recent Development
- 13.14 Acorda Therapeutics
 - 10.14.1 Acorda Therapeutics Company Details
 - 10.14.2 Acorda Therapeutics Business Overview and Its Total Revenue
 - 10.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
 - 10.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 10.14.5 Acorda Therapeutics Recent Development
- 13.15 Gilead Sciences
 - 10.15.1 Gilead Sciences Company Details
 - 10.15.2 Gilead Sciences Business Overview and Its Total Revenue
 - 10.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
 - 10.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 10.15.5 Gilead Sciences Recent Development
- 13.16 Intercept Pharmaceuticals
 - 10.16.1 Intercept Pharmaceuticals Company Details
 - 10.16.2 Intercept Pharmaceuticals Business Overview and Its Total Revenue
 - 10.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
 - 10.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
 - 10.16.5 Intercept Pharmaceuticals Recent Development
- 13.17 Shire Plc
 - 10.17.1 Shire Plc Company Details
 - 10.17.2 Shire Plc Business Overview and Its Total Revenue
 - 10.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction

10.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

10.17.5 Shire Plc Recent Development

13.18 NGM Biopharmaceuticals

10.18.1 NGM Biopharmaceuticals Company Details

10.18.2 NGM Biopharmaceuticals Business Overview and Its Total Revenue

10.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction

10.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

10.18.5 NGM Biopharmaceuticals Recent Development

13.19 Conatus Pharmaceuticals

10.19.1 Conatus Pharmaceuticals Company Details

10.19.2 Conatus Pharmaceuticals Business Overview and Its Total Revenue

10.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction

10.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

10.19.5 Conatus Pharmaceuticals Recent Development

13.20 Durect Corporation

10.20.1 Durect Corporation Company Details

10.20.2 Durect Corporation Business Overview and Its Total Revenue

10.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction

10.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

10.20.5 Durect Corporation Recent Development

13.21 Sirnaomics

10.21.1 Sirnaomics Company Details

10.21.2 Sirnaomics Business Overview and Its Total Revenue

10.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction

10.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

10.21.5 Sirnaomics Recent Development

13.22 Shenzhen HighTide Biopharmaceuticals

10.22.1 Shenzhen HighTide Biopharmaceuticals Company Details

10.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview and Its Total Revenue

10.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction

10.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

10.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Primary Sclerosing Cholangitis Treatment Key Market Segments
- Table 2. Key Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
- Table 3. Ranking of Global Top Primary Sclerosing Cholangitis Treatment Manufacturers by Revenue (US\$ Million) in 2019
- Table 4. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026
- Table 5. Key Players of Liver Transplantation Operation
- Table 6. Key Players of UDCA Drugs
- Table 7. Key Players of PSC Drugs
- Table 8. COVID-19 Impact Global Market: (Four Primary Sclerosing Cholangitis Treatment Market Size Forecast Scenarios)
- Table 9. Opportunities and Trends for Primary Sclerosing Cholangitis Treatment Players in the COVID-19 Landscape
- Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 11. Key Regions/Countries Measures against Covid-19 Impact
- Table 12. Proposal for Primary Sclerosing Cholangitis Treatment Players to Combat Covid-19 Impact
- Table 13. Global Primary Sclerosing Cholangitis Treatment Market Size Growth by Application (US\$ Million): 2020 VS 2026
- Table 14. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions (US\$ Million): 2020 VS 2026
- Table 15. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions (2015-2020) (US\$ Million)
- Table 16. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2015-2020)
- Table 17. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Regions (2021-2026) (US\$ Million)
- Table 18. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2021-2026)
- Table 19. Market Top Trends
- Table 20. Key Drivers: Impact Analysis
- Table 21. Key Challenges
- Table 22. Primary Sclerosing Cholangitis Treatment Market Growth Strategy
- Table 23. Main Points Interviewed from Key Primary Sclerosing Cholangitis Treatment

Players

Table 24. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2015-2020) (Million US\$)

Table 25. Global Primary Sclerosing Cholangitis Treatment Market Share by Players (2015-2020)

Table 26. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2019)

Table 27. Global Primary Sclerosing Cholangitis Treatment by Players Market Concentration Ratio (CR5 and HHI)

Table 28. Key Players Headquarters and Area Served

Table 29. Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service

Table 30. Date of Enter into Primary Sclerosing Cholangitis Treatment Market

Table 31. Mergers & Acquisitions, Expansion Plans

Table 32. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 33. Global Primary Sclerosing Cholangitis Treatment Market Size Share by Type (2015-2020)

Table 34. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2021-2026)

Table 35. Global Primary Sclerosing Cholangitis Treatment Market Size Share by Application (2015-2020)

Table 36. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 37. Global Primary Sclerosing Cholangitis Treatment Market Size Share by Application (2021-2026)

Table 38. North America Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US\$)

Table 39. North America Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)

Table 40. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 41. North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)

Table 42. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 43. North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)

Table 44. Europe Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US\$)

Table 45. Europe Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)

Table 46. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 47. Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)

Table 48. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 49. Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)

Table 50. China Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US\$)

Table 51. China Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)

Table 52. China Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 53. China Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)

Table 54. China Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 55. China Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)

Table 56. Japan Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US\$)

Table 57. Japan Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)

Table 58. Japan Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 59. Japan Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)

Table 60. Japan Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 61. Japan Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)

Table 62. Southeast Asia Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US\$)

Table 63. Southeast Asia Key Players Primary Sclerosing Cholangitis Treatment Market

Share (2019-2020)

Table 64. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 65. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)

Table 66. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 67. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)

Table 68. India Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US\$)

Table 69. India Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)

Table 70. India Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 71. India Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)

Table 72. India Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 73. India Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)

Table 74. Central & South America Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US\$)

Table 75. Central & South America Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)

Table 76. Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US\$)

Table 77. Central & South America Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)

Table 78. Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US\$)

Table 79. Central & South America Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)

Table 80. Allergan Company Details

Table 81. Allergan Business Overview

Table 82. Allergan Product

Table 83. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 84. Allergan Recent Development

Table 85. Glenmark Company Details

Table 86. Glenmark Business Overview

Table 87. Glenmark Product

Table 88. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 89. Glenmark Recent Development

Table 90. Impax Laboratories Company Details

Table 91. Impax Laboratories Business Overview

Table 92. Impax Laboratories Product

Table 93. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 94. Impax Laboratories Recent Development

Table 95. Mylan Company Details

Table 96. Mylan Business Overview

Table 97. Mylan Product

Table 98. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 99. Mylan Recent Development

Table 100. Teva Pharmaceuticals Company Details

Table 101. Teva Pharmaceuticals Business Overview

Table 102. Teva Pharmaceuticals Product

Table 103. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 104. Teva Pharmaceuticals Recent Development

Table 105. Dr. Falk Pharma Company Details

Table 106. Dr. Falk Pharma Business Overview

Table 107. Dr. Falk Pharma Product

Table 108. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 109. Dr. Falk Pharma Recent Development

Table 110. Daewoong Pharmaceutical Company Details

Table 111. Daewoong Pharmaceutical Business Overview

Table 112. Daewoong Pharmaceutical Product

Table 113. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 114. Daewoong Pharmaceutical Recent Development

Table 115. Epic Pharma Business Overview

Table 116. Epic Pharma Product

Table 117. Epic Pharma Company Details

- Table 118. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)
- Table 119. Epic Pharma Recent Development
- Table 120. Mitsubishi Tanabe Pharma Company Details
- Table 121. Mitsubishi Tanabe Pharma Business Overview
- Table 122. Mitsubishi Tanabe Pharma Product
- Table 123. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)
- Table 124. Mitsubishi Tanabe Pharma Recent Development
- Table 125. Lannett Company Details
- Table 126. Lannett Business Overview
- Table 127. Lannett Product
- Table 128. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)
- Table 129. Lannett Recent Development
- Table 130. Bruschettini Company Details
- Table 131. Bruschettini Business Overview
- Table 132. Bruschettini Product
- Table 133. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)
- Table 134. Bruschettini Recent Development
- Table 135. Shanghai Pharma Company Details
- Table 136. Shanghai Pharma Business Overview
- Table 137. Shanghai Pharma Product
- Table 138. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)
- Table 139. Shanghai Pharma Recent Development
- Table 140. Grindeks Company Details
- Table 141. Grindeks Business Overview
- Table 142. Grindeks Product
- Table 143. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)
- Table 144. Grindeks Recent Development
- Table 145. Acorda Therapeutics Company Details
- Table 146. Acorda Therapeutics Business Overview
- Table 147. Acorda Therapeutics Product
- Table 148. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)
- Table 149. Acorda Therapeutics Recent Development

Table 150. Gilead Sciences Company Details

Table 151. Gilead Sciences Business Overview

Table 152. Gilead Sciences Product

Table 153. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 154. Gilead Sciences Recent Development

Table 155. Intercept Pharmaceuticals Company Details

Table 156. Intercept Pharmaceuticals Business Overview

Table 157. Intercept Pharmaceuticals Product

Table 158. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 159. Intercept Pharmaceuticals Recent Development

Table 160. Shire Plc Company Details

Table 161. Shire Plc Business Overview

Table 162. Shire Plc Product

Table 163. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 164. Shire Plc Recent Development

Table 165. NGM Biopharmaceuticals Company Details

Table 166. NGM Biopharmaceuticals Business Overview

Table 167. NGM Biopharmaceuticals Product

Table 168. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 169. NGM Biopharmaceuticals Recent Development

Table 170. Conatus Pharmaceuticals Company Details

Table 171. Conatus Pharmaceuticals Business Overview

Table 172. Conatus Pharmaceuticals Product

Table 173. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 174. Conatus Pharmaceuticals Recent Development

Table 175. Durect Corporation Company Details

Table 176. Durect Corporation Business Overview

Table 177. Durect Corporation Product

Table 178. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 179. Durect Corporation Recent Development

Table 180. Sirnaomics Company Details

Table 181. Sirnaomics Business Overview

Table 182. Sirnaomics Product

Table 183. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 184. Sirnaomics Recent Development

Table 185. Shenzhen HighTide Biopharmaceuticals Company Details

Table 186. Shenzhen HighTide Biopharmaceuticals Business Overview

Table 187. Shenzhen HighTide Biopharmaceuticals Product

Table 188. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US\$)

Table 189. Shenzhen HighTide Biopharmaceuticals Recent Development

Table 190. Research Programs/Design for This Report

Table 191. Key Data Information from Secondary Sources

Table 192. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Primary Sclerosing Cholangitis Treatment Market Share by Type: 2020 VS 2026

Figure 2. Liver Transplantation Operation Features

Figure 3. UDCA Drugs Features

Figure 4. PSC Drugs Features

Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2020 VS 2026

Figure 6. Hospital Case Studies

Figure 7. Clinics Case Studies

Figure 8. Other Case Studies

Figure 9. Primary Sclerosing Cholangitis Treatment Report Years Considered

Figure 10. Global Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 11. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions: 2020 VS 2026

Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2021-2026)

Figure 13. Porter's Five Forces Analysis

Figure 14. Global Primary Sclerosing Cholangitis Treatment Market Share by Players in 2019

Figure 15. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2019)

Figure 16. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2019

Figure 17. North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 18. Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. China Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Japan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. India Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. Central & South America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. Allergan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 25. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 26. Glenmark Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 28. Impax Laboratories Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 30. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 32. Teva Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 34. Dr. Falk Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 36. Daewoong Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 38. Epic Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 40. Mitsubishi Tanabe Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 42. Lannett Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 44. Bruschettini Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis

Treatment Business (2015-2020)

Figure 46. Shanghai Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 48. Grindeks Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 50. Acorda Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 52. Gilead Sciences Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 54. Intercept Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 56. Shire Plc Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 57. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 58. NGM Biopharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 59. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 60. Conatus Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 61. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 62. Durect Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 63. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C7A7A44100ACEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7A7A44100ACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

